title: Focal or subtotal therapy for early stage prostate cancer.
abstract: Focal treatment for prostate cancer is highly intriguing, but poorly supported by the published literature. Further studies, preferably randomized controlled trials, are needed before this can be considered standard therapy. Focal treatment should be reserved for patients with focal disease. Even "clinically insignificant" synchronous tumors are malignant, and carry risk of progression if not treated with the index lesion. Whether these are likely to progress in this setting compared to those managed with active surveillance is unknown. The limited data regarding subtotal or focal cryotherapy suggest that patients properly evaluated for presence of satellite tumors have a low risk of having large unknown satellite tumors. The author requires office-based saturation biopsy prior to considering focal cryotherapy. Observation of prostatic intraepithelial neoplasia (PIN), atypical findings (ASAP), or cancer on the contralateral biopsy cores excludes the patient from consideration of subtotal therapy. MRI offers a potential additional ability to detect occult contralateral tumors. Younger men paradoxically seem to have greater interest in focal therapy while having a higher risk of future malignancy in the untreated areas based on the years of potential risk. However, no age cutoff is established. Without published data to support its use, lumpectomy or freezing only the focus where cancer is believed to exist, will remain limited. Hemispheric or subtotal treatment decreases the amount of untreated tissue. As a result, the local failure rate would be predicted to be lower but is unknown. When performing subtotal treatment, the author freezes almost the entire gland, sparing only the aspect adjacent to the contralateral neurovascular bundle, and has found this practice to be of highly limited utility based on the issues described. Biopsy should be performed following any treatment that fails to target the entire gland. A positive biopsy should be dealt with based on clinical factors as if the patient had not been treated, and a positive biopsy should not preclude active surveillance if deemed appropriate.
authors: Urological Institute, The Cleveland Clinic Foundation, 9500 Euclid Ave St. A100, Cleveland, OH 44195, USA. jonesS7@ccf.org
authors: J Stephen
authors: JS
authors: Jones
mesh_terms: D001918:Brachytherapy / Q000379:methods; D017679:Cryotherapy / Q000379:methods; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology / Q000628:therapy*; D014463:Ultrasonography
references: Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):429-38
references: 11872289
references: Semin Nucl Med. 2007 Jan;37(1):17-28
references: 17161036
references: Brachytherapy. 2007 Jan-Mar;6(1):16-25
references: 17284381
references: Cancer. 1972 Jul;30(1):5-13
references: 5064808
references: J Urol. 2004 Apr;171(4):1520-4
references: 15017211
references: Urology. 2002 Jul;60(1):109-14
references: 12100934
references: Technol Cancer Res Treat. 2004 Aug;3(4):365-70
references: 15270587
references: J Urol. 2002 Aug;168(2):500-3
references: 12131297
references: Technol Cancer Res Treat. 2007 Apr;6(2):91-5
references: 17375971
references: Urology. 2005 Jul;66(1):114-8
references: 15992910
references: Urology. 2002 Aug;60(2 Suppl 1):3-11
references: 12206842
references: Urology. 2001 Jun;57(6):1112-6
references: 11377320
references: Urology. 2002 Oct;60(4):645-9
references: 12385926
references: J Urol. 1998 Mar;159(3):915-9
references: 9474182
references: Urology. 2007 Feb;69(2):306-10
references: 17320669
references: Eur Urol. 2007 Feb;51(2):381-7
references: 16857310
references: J Urol. 1994 Jun;151(6):1571-4
references: 7514690
references: Urology. 2006 Nov;68(5):1037-41
references: 17095067
references: Cancer. 1992 Nov 1;70(9):2313-8
references: 1382830
references: J Urol. 1999 Nov;162(5):1649-52
references: 10524890
references: Urology. 1999 Nov;54(5):846-52
references: 10565745
references: Eur Radiol. 2004 Feb;14(2):309-17
references: 14531000
references: J Urol. 2006 Oct;176(4 Pt 1):1376-81; discussion 1381
references: 16952636
references: Int J Impot Res. 1996 Jun;8(2):91-4
references: 8858398
references: Eur Urol. 2006 Dec;50(6):1163-74; discussion 1175
references: 16842903
references: World J Urol. 2006 Nov;24(5):585-90
references: 16850340
references: Urology. 2002 Aug;60(2 Suppl 1):34-9
references: 12206846
references: Urology. 2002 Aug;60(2 Suppl 1):19-25
references: 12206844
references: Med Dosim. 2007 Summer;32(2):71-9
references: 17472885
references: Am J Surg Pathol. 1992 Apr;16(4):315-24
references: 1373577
references: Radiology. 1997 Jun;203(3):645-52
references: 9169683
references: J Urol. 1999 Aug;162(2):433-8
references: 10411052
references: J Endourol. 2006 Sep;20(9):688-92
references: 16999628
references: Cancer Res. 1995 Aug 1;55(15):3346-51
references: 7542168
references: Eur Urol. 2006 Sep;50(3):498-505
references: 16631303